Key result
AAV-Lmna/DJ8 increases body weight ~47% and prolongs survival in neonatal Lmna-/- mice.
Why the study?
Mutations in LMNA cause laminopathies that frequently present as DCM, motivating investigation into whether cardiomyocyte re-expression of lamin A can rescue the severe phenotype of Lmna-/- mice.
Does AAV-Lmna/DJ8 gene replacement improve cardiac function and survival in Lmna-/- mice?
Does AAV-Lmna/DJ8 gene replacement improve cardiac function and survival in Lmna-/- mice?
Absolute Event Rate: 5.86% vs 3.98%
p-value: p=4.45 × 10⁻⁴
AAV-mediated LMNA gene replacement restores oxidative phosphorylation gene programs and partially ameliorates cardiac dysfunction and survival in a mouse model of laminopathy-associated cardiomyopathy.
Gene therapy approach in Lmna−/− mice remains preclinical; leaves open translation to human laminopathy cardiomyopathy.
Mutations in LMNA , which encodes the nuclear envelope protein lamin A/C, cause laminopathies that frequently present as dilated cardiomyopathy (DCM). We investigated whether re-expression of lamin A in cardiomyocytes can rescue the severe phenotype of Lmna −/− mice. An adeno-associated virus vector expressing wild-type Lmna (AAV- Lmna /DJ8) was administered intrathoracically to neonatal mice. Three weeks after injection, treated Lmna −/− mice exhibited robust cardiac Lmna mRNA induction and correct nuclear localization of lamin A protein, indicating efficient cardiotropic gene delivery. Compared with PBS treatment, AAV- Lmna /DJ8 treatment promoted body weight maintenance, improved left ventricular systolic function, and significantly prolonged survival in Lmna −/− mice. To explore the underlying mechanisms, we performed single-nucleus RNA sequencing of cardiomyocytes from wild-type mice, PBS-treated Lmna −/− mice, and AAV- Lmna /DJ8–treated Lmna −/− mice. AAV-mediated lamin A re-expression shifted the cardiomyocyte transcriptome toward the wild-type profile, and restored oxidative phosphorylation–related gene programs, which were diminished in untreated Lmna −/− mice. These findings demonstrate that targeted re-expression of Lmna partially ameliorates cardiac dysfunction in Lmna −/− mice and highlight the therapeutic potential of LMNA gene replacement for laminopathy-associated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Izawa et al. (2026) studied Dilated cardiomyopathy (LMNA deficiency). AAV-Lmna/DJ8 vs. PBS was evaluated on Body weight at postnatal day 22 (g) (p=4.45 × 10⁻⁴). Intrathoracic administration of AAV-Lmna/DJ8 in neonatal Lmna-/- mice significantly improved body weight (5.86 g vs 3.98 g), increased cardiomyocyte cross-sectional area, and prolonged survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: